The Body PRO Covers: The XIV International AIDS Conference

Durability and Tolerability of ABC/AZT/3TC

July 9, 2002

  • Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine (ABC/AZT/3TC) Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (TuPeB4453)
    Authored by P. Gute, B. Dauer, T. Stark, A. Haberl, M. Bickel, V. Rickerts, B. Jennings, S. Staszewski
    View the original abstract

Many cohort studies have reported a high frequency of changes in HAART regimens over time (i.e., percent of patients who change their first regimen within the first 18 months). Gute and colleagues from Frankfurt evaluated 183 patients started on abacavir/zidovudine/lamivudine (ABC/AZT/3TC) as their first regimen for whom CD4 and RNA data was available. Sixty percent were still on their initial regimen after a median of 20 months (40 percent switched or stopped).

The initial median viral load for the cohort was 5.05 log and the CD4 count was 217. There were eight cases of abacavir hypersensitivity reaction (4 percent). AZT was switched to d4T in 17 patients due to intolerance. Overall, 29 patients (15 percent) stopped HAART completely. The authors conclude that this triple NRTI regimen is simple and well tolerated.

I would comment that the results are equivalent or superior compared to many published reports regarding the tolerability/durability of the initial regimen. The virologic criteria for success was not discussed (i.e., didn't use less than 50 copies/ml as the target), so that may have impacted the results.

Previous Session | Next Session

Tell us what you think of The Body's conference coverage!

This article was provided by TheBodyPRO. It is a part of the publication The XIV International AIDS Conference.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.